A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis

SIMPLE SUMMARY: This study is one of the very few phase I trials on intraperitoneal chemotherapy applied as PIPAC. Cisplatin and doxorubicin may be safely used as PIPAC at a dose of 30 mg/m(2) and 6 mg/m(2), respectively; oxaliplatin can be used at an intraperitoneal dose of 135 mg/m(2). No serious...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancers (Basel)
Prif Awduron: Robella, Manuela, De Simone, Michele, Berchialla, Paola, Argenziano, Monica, Borsano, Alice, Ansari, Shoeb, Abollino, Ornella, Ficiarà, Eleonora, Cinquegrana, Armando, Cavalli, Roberta, Vaira, Marco
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958944/
https://ncbi.nlm.nih.gov/pubmed/33802269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051060
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg